Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Versant Launches Inception IBD, A New Company With Old Roots

This article was originally published in Start Up

Executive Summary

Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.


Related Content

Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
Versant Continues “Build-To-Buy” With New Fund
BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale


Related Companies

Related Deals